Clinical trial
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
NCT00407563 · Accelerated Community Oncology Research Network, Other · Completed
Key facts
| NCT number | NCT00407563 |
|---|---|
| Title | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer |
| Official title | A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | Accelerated Community Oncology Research Network, Other |
| Collaborators | Genentech, Inc. Industry Celgene Corporation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma |
| Intervention type | Drug |
| Interventions | Bevacizumab, Abraxane |
| Enrollment | 48 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Dec 5, 2006 |
| Last update posted | Apr 5, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: